Austar Lifesciences (HKG:6118) Strong Profits May Be Masking Some Underlying Issues

The recent earnings posted by Austar Lifesciences Limited (HKG:6118) were solid, but the stock didn't move as much as we expected. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

We've discovered 3 warning signs about Austar Lifesciences. View them for free.

How Do Unusual Items Influence Profit?

For anyone who wants to understand Austar Lifesciences' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥4.5m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. And, after all, that's exactly what the accounting terminology implies. If Austar Lifesciences doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Austar Lifesciences.

Our Take On Austar Lifesciences' Profit Performance

Arguably, Austar Lifesciences' statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Austar Lifesciences' true underlying earnings power is actually less than its statutory profit. The good news is that it earned a profit in the last twelve months, despite its previous loss. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Case in point: We've spotted 3 warning signs for Austar Lifesciences you should be mindful of and 1 of these is significant.

Today we've zoomed in on a single data point to better understand the nature of Austar Lifesciences' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.